OTC Homeopathic Claims Go Under FTC Microscope, Potential For Regulatory Shift Magnifies
This article was originally published in The Tan Sheet
Executive Summary
FTC says the homeopathic market “shifted from one based primarily on formulations prescribed for an individual user to mass-market formulations widely advertised and sold nationwide in major retail stores.” The workshop could signal FTC interest in asking for clinical trials to support for OTC homeopathic claims.
You may also be interested in...
Homeopathic Regulatory Evaluation Stocked With FDA Concerns, Industry Answers
The industry wants FDA to consider that a fraction of poison control reports are for homeopathics compared to other drugs and the agency’s current enforcement authorities maintain compliance in manufacturing and marketing the products. FDA is considering whether to maintain its policy that recognizes an ingredient’s inclusion in the HPUS monograph as pre-market approval.
Homeopathic Claims Have FTC Searching For Remedy To Regulatory Conflict With FDA
FTC shuts down the second marketer this year for making fraudulent claims for human chorionic gonadotropin weight-loss products. Enforcing against other homeopathics’ claims that violate advertising regulations, however, is on hold until FTC resolves its differences with FDA’s regulatory oversight of the products.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.